Bone marrow deficient in IFN-γ signaling selectively reverses GVHD-associated immunosuppression and enhances a tumor-specific GVT effect

Blood

Volumn 113, Issue 20, 2009, Pages 5002-5009

  Capitini, Christian M ^a   Herby, Sarah ^a   Milliron, Matthew ^a   Anver, Miriam R ^b   Mackall, Crystal L ^a   Fry, Terry J ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR 1; MINOR HISTOCOMPATIBILITY ANTIGEN; GAMMA INTERFERON RECEPTOR; INTERFERON RECEPTOR;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DEPRESSION; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT VERSUS HOST REACTION; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL DEPLETION; T LYMPHOCYTE; ANIMAL; BIOLOGICAL MODEL; C3H MOUSE; C57BL MOUSE; ENZYME SPECIFICITY; GENETICS; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOLOGY; MALE; METABOLISM; METHODOLOGY; MOUSE MUTANT; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; TUMOR ESCAPE;

ANIMALS; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; IMMUNOSUPPRESSION; INTERFERON-GAMMA; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, BIOLOGICAL; RECEPTORS, INTERFERON; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY; TRANSPLANTATION CONDITIONING; TUMOR CELLS, CULTURED; TUMOR ESCAPE;

EID: 66549119153     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-11-187385     Document Type: Article

References (40)

1. Hambach L, Goulmy E. Immunotherapy of cancer through targeting of minor histocompatibility antigens. Curr Opin Immunol. 2005;17:202-210. (Pubitemid 40343109)
2. Mundhada SSJ, Mori S, Savary CA, CA Mullen. Cellular tumor vaccines administered after T cell-depleted allogeneic bone marrow transplantation induce effective anti-tumor immune responses. Leuk Lymphoma. 2005;46:571-580. (Pubitemid 40584874)
3. Hollenbaugh JA, Dutton RW. IFN-γ regulates donor CD8 T cell expansion, migration, and leads to apoptosis of cells of a solid tumor. J Immunol. 2006;177:3004-3011.
4. Hill GR, Teshima T, Gerbitz A, et al. Differential roles of IL-1 and TNF-α on graft-versus-host disease and graft versus leukemia. J Clin Invest. 1999;104:459-467. (Pubitemid 29534330)
5. Yang YG, Wang HH, Asavaroengchai W, Dey BR. Role of interferon-gamma in GVHD and GVL. Cell Mol Immunol. 2005;2:323-329.
6. + T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med. 2007;13:354-360. (Pubitemid 46376686)
7. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5:375-386.
8. Puliaev R, Nguyen P, Finkelman FD, Via CS. Differential requirement for IFN-γ in CTL maturation in acute murine graft-versus-host disease. J Immunol. 2004;173:910-919. (Pubitemid 38924264)
9. Seddik M, Seemayer TA, Lapp WS. The graft-versus-host reaction and immune function: I. T helper cell immunodeficiency associated with graft-versus-host-induced thymic epithelial cell damage. Transplantation. 1984;37:281-286.
10. Witherspoon RP, Matthews D, Storb R, et al. Recovery of in vivo cellular immunity and bone marrow grafting: influence of time postgrafting and acute graft-versus-host disease. Transplantation. 1984;37:145-150. (Pubitemid 14191879)
11. Gratwohl A, Hermans J, Apperley J, et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood. 1995;86:813-818.
12. Anderson LD Jr, Savary CA, Mullen CA. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus- host disease. Blood. 2000;95:2426-2433. (Pubitemid 30167746)
13. Teshima T, Mach N, Hill GR, et al. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res. 2001;61:162-171. (Pubitemid 32095714)
14. Melchionda F, McKirdy M, Medeiros F, Fry T, Mackall C. Escape from immune surveillance does not result in tolerance to tumor-associated antigens. J Immunother. 2004;27:329-338. (Pubitemid 39121921)
15. Borrello I, Sotomayor EM, Rattis F-M, Cooke SK, Gu L, Levitsky HI. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood. 2000;95:3011-3019. (Pubitemid 30321148)
16. Cui Y, Kelleher E, Straley E, et al. Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells. Nat Med. 2003;9:952-958. (Pubitemid 36889940)
17. Kwak LW, Campbell MJ, Zelenetz AD, Levy R. Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy. Blood. 1991;78:2768-2772.
18. Anderson LD Jr, Mori S, Mann S, Savary CA, Mullen CA. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease. Cancer Res. 2000;60:5797-5802. (Pubitemid 30808317)
19. Ljungman P, Lewensohn-Fuchs I, Hammarstrom V, et al. Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantation. Blood. 1994;84:657-663. (Pubitemid 24215971)
20. Lum LG. The kinetics of immune reconstitution after human marrow transplantation. Blood. 1987;69:369-380. (Pubitemid 17022001)
21. Mackall CL, Gress RE. Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Immunol Rev. 1997;157:61-72.
22. Crooks GM, Weinberg K, Mackall C. Immune reconstitution: from stem cells to lymphocytes. Biol Blood Marrow Transplant. 2006;12:42-46. (Pubitemid 43034118)
23. + T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice. J Exp Med. 1987;165:1552-1564. (Pubitemid 17087907)
24. Fry T, Shand J, Milliron M, Tasian S, Mackall C. Antigen loading of DCs with irradiated apoptotic tumor cells induces improved anti-tumor immunity compared with other approaches. Cancer Immunol Immunother. Prepublished on January 13, 2009, as DOI 10.1007/s00262-008-0638-647
25. + memory cell pool. J Clin Invest. 2005;115:1177-1187. (Pubitemid 40629036)
26. Fry TJ, Christensen BL, Komschlies KL, Gress RE, Mackall CL. Interleukin-7 restores immunity in athymic T-cell-depleted hosts. Blood. 2001;97:1525-1533.
27. Sinha ML, Fry TJ, Fowler DH, Miller G, Mackall CL. Interleukin 7 worsens graft-versus-host disease. Blood. 2002;100:2642-2649.
28. Mullen CA. Influence of tumor vaccines on graft versus tumor activity and graft versus host disease in allogeneic bone marrow transplantation. Leuk Lymphoma. 2002;43:503-510. (Pubitemid 34232916)
29. Teshima T, Liu C, Lowler KP, Dranoff G, Ferrara JLM. Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation. Cancer Res. 2002;62:796-800. (Pubitemid 34126956)
30. Sun Y, Tawara I, Toubai T, Reddy P. Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res. 2007;150:197-214. (Pubitemid 47444613)
31. Meunier M-C, Delisle J-S, Bergeron J, Rineau V, Baron C, Perreault C. T cells targeted against a single minor histocompatibility antigen can cure solid tumors. Nat Med. 2005;11:1222-1229. (Pubitemid 43093670)
32. Igarashi T, Wynberg J, Srinivasan R, et al. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood. 2004;104:170-177. (Pubitemid 38879854)
33. Hallett WHD, Murphy WJ. Natural killer cells: biology and clinical use in cancer therapy. Cell Mol Immunol. 2004;1:12-21.
34. Voutsadakis IA. NK cells in allogeneic bone marrow transplantation. Cancer Immunol Immunother. 2003;52:525-534. (Pubitemid 37056127)
35. Reed JM, Branigan PJ, Bamezai A. Interferon gamma enhances clonal expansion and survival of CD4+ T cells. J Interferon Cytokine Res. 2008;28:611-622.
36. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412-415. (Pubitemid 29343964)
37. Welniak LA, Blazar BR, Anver MR, Wiltrout RH, Murphy WJ. Opposing roles of interferon-gamma on CD4+ T cell-mediated graft-versus-host disease: effects of conditioning. Biol Blood Marrow Transplant. 2000;6:604-612.
38. Burman AC, Banovic T, Kuns RD, et al. IFNγ differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. Blood. 2007;110:1064-1072. (Pubitemid 47267449)
39. Rao AR, Quinones MP, Garavito E, et al. CC chemokine receptor 2 expression in donor cells serves an essential role in graft-versus-host disease. J Immunol. 2003;171:4875-4885. (Pubitemid 37310610)
40. Matte CC, Liu J, Cormier J, et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med. 2004;10:987-992. (Pubitemid 39273741)